Back to Archived News
Ikonisys Awarded Patent for the Process for Identifying FISH Signals
Tuesday, March 23, 2010
New Haven, CT -- Ikonisys, Inc., a leading provider of next-generation, cell-based diagnostic solutions, announced today that the United States Patent and Trademark Office has issued the company United States Patent No. 7,660,454 entitled "Process for identifying FISH signals."
The ‘454 patent describes a process for identifying fluorescence in-situ hybridization (FISH) signals with an epi-fluorescence microscope using a multi-focal plane technology. This patent describes a method for the acquisition of images on multiple focal planes, followed by combination and analysis of those images to detect desired signals. In automated microscopy, diagnostically accurate detection of multiple FISH signals within a nucleus, requires capturing and analyzing images in multiple focal planes.
With this patent, Ikonisys extends its intellectual property portfolio to cover the image analysis process of its proprietary software package that is run on the Ikoniscope® Digital Microscopy System. Ikonisys has a suite of applications to be run on the Ikoniscope, which uses the CellOptics® technology.
Dr. Triantafyllos Tafas, CTO of Ikonisys, commented, "This patent not only reinforces our dominant position in our specific market but also demonstrates to our customers that we are pioneers in the medical digital image-analysis industry."
About Ikonisys
Founded in 1999, Ikonisys, Inc. is a privately-held, next generation diagnostic company specializing in non-invasive, cell-based diagnostics. Ikonisys has developed the CellOptics platform, a robotic microscopy technology for fully-automated, high-throughput identification and analysis of rare cells by fluorescence in-situ hybridization (FISH).
A pipeline of applications is being developed for cancer diagnosis and management (oncoFISH®) and a non-invasive prenatal screening test for Down syndrome (fastFISH® fetal) to be run on the Ikoniscope using the CellOptics technology. Additionally, Ikonisys has developed a novel approach for the enrichment, identification and characterization of circulating tumor cells (CTC).
Ikonisys’ first proprietary test, oncoFISH® cervical, is offered as a Laboratory Developed Test through the Company’s CAP-accredited clinical laboratory. In addition to oncoFISH cervical, the Company offers three FDA-cleared applications that automate certain commercially available FISH tests.
To learn more visit www.ikonisys.com.
Back to Archived News
